🚀 VC round data is live in beta, check it out!
Searle Co. Valuation Multiples
Discover revenue and EBITDA valuation multiples for Searle Co. and similar public comparables like NeOnc, Sensorion, Diamyd Medical, Humacyte and more.
Searle Co. Overview
About Searle Co.
The Searle Co Ltd is principally engaged in the manufacturing and sale of pharmaceutical, consumer health, and nutritional products. It manufactures and sells products such as Semavi, Dalimab, Extor, Tramal, Rotec, Hylixi, Emsyn, and many more, focusing on various therapeutic areas like cardiovascular, antibiotics, nutrition, respiratory care, gastroenterology, oncology, hepatology, neurology and psychiatry, probiotics, antibiotics, and nutritional care. Additionally, the group offers medical devices and disposables, health supplements, and various nutritional consumable products. The majority of the group's revenue consists of pharmaceutical sales. Geographically, it generates maximum revenue from Pakistan, and rest from Sri Lanka, Cambodia, Myanmar, Oman, Vietnam, and other countries.
Founded
1965
HQ
Employees
3.3K
Website
Sectors
Financials (FY)
EV
$240M
Searle Co. Financials
Searle Co. reported last fiscal year revenue of $102M and EBITDA of $17M.
In the same fiscal year, Searle Co. generated $50M in gross profit, $17M in EBITDA, and had net loss of ($5M).
Revenue (LTM)
Searle Co. P&L
In the most recent fiscal year, Searle Co. reported revenue of $102M and EBITDA of $17M.
Searle Co. expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $102M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $50M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 49% | XXX | XXX | XXX |
| EBITDA | — | XXX | $17M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 16% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 12% | XXX | XXX | XXX |
| Net Profit | — | XXX | ($5M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (5%) | XXX | XXX | XXX |
| Net Debt | — | — | $27M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Searle Co. Stock Performance
Searle Co. has current market cap of $213M, and enterprise value of $240M.
Market Cap Evolution
Searle Co.'s stock price is $0.36.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $240M | $213M | 0.0% | XXX | XXX | XXX | $-0.01 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSearle Co. Valuation Multiples
Searle Co. trades at 2.3x EV/Revenue multiple, and 14.5x EV/EBITDA.
EV / Revenue (LTM)
Searle Co. Financial Valuation Multiples
As of March 21, 2026, Searle Co. has market cap of $213M and EV of $240M.
Equity research analysts estimate Searle Co.'s 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Searle Co. has a P/E ratio of (42.5x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $213M | XXX | $213M | XXX | XXX | XXX |
| EV (current) | $240M | XXX | $240M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 2.3x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 14.5x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 19.8x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 4.8x | XXX | XXX | XXX |
| P/E | — | XXX | (42.5x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (32.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Searle Co. Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Searle Co. Margins & Growth Rates
Searle Co.'s revenue in the last fiscal year declined by (1%).
Searle Co. Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (1%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 16% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 39% | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 19% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 3% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 37% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Searle Co. Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| NeOnc | XXX | XXX | XXX | XXX | XXX | XXX |
| Sensorion | XXX | XXX | XXX | XXX | XXX | XXX |
| Diamyd Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Humacyte | XXX | XXX | XXX | XXX | XXX | XXX |
| Mycenax Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Searle Co. M&A Activity
Searle Co. acquired XXX companies to date.
Last acquisition by Searle Co. was on XXXXXXXX, XXXXX. Searle Co. acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Searle Co.
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSearle Co. Investment Activity
Searle Co. invested in XXX companies to date.
Searle Co. made its latest investment on XXXXXXXX, XXXXX. Searle Co. invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Searle Co.
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Searle Co.
| When was Searle Co. founded? | Searle Co. was founded in 1965. |
| Where is Searle Co. headquartered? | Searle Co. is headquartered in Pakistan. |
| How many employees does Searle Co. have? | As of today, Searle Co. has over 3K employees. |
| Who is the CEO of Searle Co.? | Searle Co.'s CEO is Tahir Ahmed. |
| Is Searle Co. publicly listed? | Yes, Searle Co. is a public company listed on Pakistan Stock Exchange. |
| What is the stock symbol of Searle Co.? | Searle Co. trades under SEARL ticker. |
| Who are competitors of Searle Co.? | Searle Co. main competitors are NeOnc, Sensorion, Diamyd Medical, Humacyte. |
| What is the current market cap of Searle Co.? | Searle Co.'s current market cap is $213M. |
| What is the current revenue of Searle Co.? | Searle Co.'s last fiscal year revenue is $102M. |
| What is the current EV/Revenue multiple of Searle Co.? | Current revenue multiple of Searle Co. is 2.3x. |
| Is Searle Co. profitable? | No, Searle Co. is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.